During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

Opdualag—which is a combination of BMS’ PD-1 inhibitor Opdivo and its lymphocyte ... plan to expand Opdualag’s ability to treat melanoma patients. Its current approval covers those age ...

Iovance Biotherapeutics, Inc. sees mixed TIL therapy success with Amtagvi in PD-1-refractory melanoma. Click here to find out ...

Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.

Whereas Opdivo blocks the checkpoint protein PD-1 on T cells, Opdualag blocks a different ... the FDA approved Opdualag as a treatment for advanced cases of melanoma, making the immunotherapy ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further ...

The PD-1 Inhibitor Drugs Market is expanding due to the rising prevalence of cancer and autoimmune diseases. PD-1 inhibitors, including pembrolizumab, nivolumab, and cemiplimab, play a crucial role in ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...